Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Etude double insu And NotJoseph H. Friedman

List of bibliographic references

Number of relevant bibliographic references: 55.
Ident.Authors (with country if any)Title
000216 Bruno Dubois [France] ; Eduardo Tolosa [Espagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Gunther Schumann [Allemagne] ; Emmanuelle Pourcher [Canada] ; Julian Gray [Suisse] ; Gail Thomas [Royaume-Uni] ; Jina Swartz [Royaume-Uni] ; Timothy Hsu [États-Unis] ; Margaret L. Moline [États-Unis]Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study
000370 Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit [Turquie] ; Pinar Unsalan [Turquie] ; Hilal Horozoglu [Turquie] ; Nese Tuncer [Turquie] ; Aynur Feyzioglu [Turquie] ; Dilek Ince Gunal [Turquie] ; Gorsev G. Yener [Turquie] ; Raif Cakmur [Turquie] ; Huseyin A. Sahin [Turquie] ; Murat Emre [Turquie]The Effects of Rasagiline on Cognitive Deficits in Parkinson's Disease Patients Without Dementia: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
000409 Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni]Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, Placebo-Controlled Study (RECOVER)
000543 Helge Hellriegel [Allemagne] ; Jan Raethjen [Allemagne] ; G. Deuschl [Allemagne] ; Jens Volkmann [Allemagne]Levetiracetam in Primary Orthostatic Tremor: A Double-Blind Placebo-Controlled Crossover Study
000692 Arianna Guidubaldi [Italie] ; Alfonso Fasano [Italie] ; Tamara Lalongo [Italie] ; Carla Piano [Italie] ; Maurizio Pompili [Italie] ; Roberta Masciana [Italie] ; Luisa Siciliani [Italie] ; Mario Sabatelli [Italie] ; Anna Rita Bentivoglio [Italie]Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease
000796 Endre Pal [Hongrie] ; Ferenc Nagy [Hongrie] ; Zsuzsanna Aschermann [Hongrie] ; Eva Balazs [Hongrie] ; Norbert Kovacs [Hongrie]The Impact of Left Prefrontal Repetitive Transcranial Magnetic Stimulation on Depression in Parkinson's Disease: a Randomized, Double-Blind, Placebo-Controlled Study
000928 Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Cesaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible Sublingual Piribedil to Abort OFF Episodes: A Single Dose Placebo-Controlled, Randomized, Double-Blind, Cross-Over Study
000A99 Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas]Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease
000C41 Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande]A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease
000D18 Gottfried Kranz [Autriche] ; Dietrich Haubenberger [Autriche] ; Bemhard Voller [Autriche] ; Martin Posch [Autriche] ; Peter Schnider [Autriche] ; Eduard Auff [Autriche] ; Thomas Sycha [Autriche]Respective Potencies of Botox® and Dysport® in a Human Skin Model : A Randomized, Double-blind Study
001316 David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France]Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study
001429 Tanya Gurevich [Israël] ; Chava Peretz [Israël] ; Orna Moore [Israël] ; Nina Weizmann [Israël] ; Nir Giladi [Israël]The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : A double blind placebo-controlled pilot study
001476 Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France]Safety and tolerability of growth hormone therapy in multiple system atrophy : A double-blind, placebo-controlled study
001477 Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni]Rotigotine Transdermal Patch in Early Parkinson's Disease : A Randomized, Double-Blind, Controlled Study Versus Placebo and Ropinirole
001533 Yoshikuni Mizuno [Japon] ; Ichiro Kanazawa [Japon] ; Sadako Kuno [Japon] ; Nobuo Yanagisawa [Japon] ; Mitsutoshi Yamamoto [Japon] ; Tomoyoshi Kondo [Japon]Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating Parkinsonian patients
001688 Wolfgang H. Oertel [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Bettina Bergtholdt [Allemagne] ; Yngve Hallström [Suède] ; Jaan Albo [Suède] ; Lena Leissner [Suède] ; Thomas Schindler [Allemagne] ; Juergen Koester [Allemagne] ; Juergen Reess [Allemagne]Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study)
001695 Jose M. Rabey [Israël] ; Tatiana Prokhorov ; Ala Miniovitz ; Eugenia Dobronevsky ; Colin KleinEffect of quetiapine in psychotic parkinson's disease patients : A double-blind labeled study of 3 months' duration
001806 Jaime Kulisevsky [Espagne] ; Berta Pascual-Sedano [Espagne] ; Manel Barbanoj [Espagne] ; Alexandre Gironell [Espagne] ; Javier Pagonabarraga [Espagne] ; Carmen Garcia-Sanchez [Espagne]Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease : A double-blind study
001869 Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease
001B11 Alexei Korchounov [Allemagne, Égypte] ; Gregory Bogomazov [Russie]Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy
001C04 Giovanni Lagalla [Italie] ; Marzia Millevolte [Italie] ; Marianna Capecci [Italie] ; Leandro Provinciali [Italie] ; Maria Gabriella Ceravolo [Italie]Botulinum toxin type a for drooling in Parkinson's disease : A double-blind, randomized, placebo-controlled study
001E55 Adrian Cristian [États-Unis] ; Meredith Katz [États-Unis] ; Eileen Cutrone [États-Unis] ; Ruth H. Walker [États-Unis]Evaluation of acupuncture in the treatment of Parkinson's disease : A double-blind pilot study
001E58 Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study
001E62 Daniel Truong [États-Unis] ; Drake D. Duane [États-Unis] ; Joseph Jankovic [États-Unis] ; Carlos Singer [États-Unis] ; Lauren C. Seeberger [États-Unis] ; Cynthia L. Comella [États-Unis] ; Mark F. Lew [États-Unis] ; Robert L. Rodnitzky [États-Unis] ; Fabio O. Danisi [États-Unis] ; James P. Sutton [États-Unis] ; P. David Charles [États-Unis] ; Robert A. Hauser [États-Unis] ; Geoffrey L. Sheean [États-Unis]Efficacy and safety of botulinum type A toxin (dysport) in cervical dystonia : Results of the first us randomized, double-blind, placebo-controlled study
002061 Karin Stiasny-Kolster [Allemagne] ; Ralf Kohnen [Allemagne] ; Erwin Schollmayer [Allemagne] ; J. Carsten Möller [Allemagne] ; Wolfgang H. Oertel [Allemagne]Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of Restless Legs Syndrome: A double-blind, placebo-controlled pilot study
002343 Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni]Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor
002344 Yoshikuni Mizuno [Japon] ; Nobuo Yanagisawa [Japon] ; Sadako Kuno [Japon] ; Mitsutoshi Yamamoto [Japon] ; Kazuko Hasegawa [Japon] ; Hideki Origasa [Japon] ; Hisayuki Kowa [Japon]Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
002345 Charles H. Adler [États-Unis] ; John N. Caviness [États-Unis] ; Joseph G. Hentz [États-Unis] ; Marlene Lind [États-Unis] ; Judy Tiede [États-Unis]Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease
002387 Claudia Trenkwalder [Allemagne] ; Victor Collado Seidel [Allemagne] ; Jörg Kazenwadel [Suisse] ; Thomas C. Wetter [Allemagne] ; Wolfgang Oertel [Allemagne] ; Roland Selzer [Allemagne] ; Ralf Kohnen [Allemagne]One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?
002406 Rajesh Pahwa [États-Unis] ; Kelly E. Lyons [États-Unis]Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study
002419 Jau-Shin Lou [États-Unis] ; Greg Kearns [États-Unis] ; Theodore Benice [États-Unis] ; Barry Oken [États-Unis] ; Gary Sexton [États-Unis] ; John Nutt [États-Unis]Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study
002467 Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France]Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study
002477 Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni]Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest Tremor and UPDRS part III in Parkinson's disease
002478 Francesca Mancini [Italie] ; Roberta Zangaglia [Italie] ; Silvano Cristina [Italie] ; Maria Grazia Sommaruga [Italie] ; Emilia Martignoni [Italie] ; Giuseppe Nappi [Italie] ; Claudio Pacchetti [Italie]Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of Drooling in parkinsonism
002630 Susan H. Fox [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; A. Peter Moore [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
002843 C. Detrembleur [Belgique] ; T. M. Lejeune [Belgique] ; A. Renders [Belgique] ; P. Y. K. Van Den Bergh [Belgique]Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy
002884 J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis]Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study
002966 Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie]Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life
002973 Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie]Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study
002C00 W. Ondo [États-Unis] ; C. Hunter [États-Unis] ; K. Dat Vuong [États-Unis] ; K. Schwartz [États-Unis] ; Joseph Jankovic [États-Unis]Gabapentin for Essential tremor : A multiple-dose, double-blind, placebo-controlled trial
002C52 E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche]Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease
002E46 T. Mezaki [Japon] ; R. Kaji [Japon] ; M. F. Brin [États-Unis] ; M. Hirota-Katayama [Japon] ; T. Kubori [Japon] ; T. Shimizu [Japon] ; J. Kimura [Japon]Combined use of type A and F botulinum toxins for blepharospasm : A double-blind controlled trial
002E73 R. Ceravolo [Italie] ; S. Salvetti [Italie] ; P. Piccini [Royaume-Uni] ; C. Lucetti [Italie] ; G. Gambaccini [Italie] ; U. Bonuccelli [Italie]Acute and chronic effects of clozapine in essential tremor
002F25 A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; F. Stocchi [Italie]Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study
002F26 Olivier Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie]Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study
003030 Olivier Rascol [France] ; K. Sieradzan [Royaume-Uni] ; H. Peyro-Saint-Paul [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; J. M. Senard [France] ; P. Ladure [France] ; J. L. Montastruc [France] ; A. Lees [Royaume-Uni]Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy
003035 R. Pahwa [États-Unis] ; K. Lyons [États-Unis] ; J. P. Hubble [États-Unis] ; K. Busenbark [États-Unis] ; J. D. Rienerth [États-Unis] ; A. Pahwa [États-Unis] ; W. C. Koller [États-Unis]Double-blind controlled trial of gabapentin in essential tremor
003096 R. A. Hauser [États-Unis] ; E. Molho [États-Unis] ; H. Shale [États-Unis] ; S. Pedder [États-Unis] ; E. E. Dorflinger [États-Unis]A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
003097 R. B. Jr Dewey [États-Unis] ; D. M. Maraganore [États-Unis] ; J. E. Ahlskog [États-Unis] ; J. Y. Matsumoto [États-Unis]A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease
003295 P. G. Como [États-Unis] ; A. J. Rubin [États-Unis] ; C. F. O'Brien [États-Unis] ; K. Lawler [États-Unis] ; C. Hickey [États-Unis] ; A. E. Rubin [États-Unis] ; R. Henderson [États-Unis] ; M. P. Mcdermott [États-Unis] ; T. Mcdermott [États-Unis] ; K. Steinberg [États-Unis] ; I. Shoulson [États-Unis]A controlled trial of fluoxetine in nondepressed patients with Huntington's disease
003501 T. L. Davis [États-Unis] ; M. Roznoski ; R. S. BurnsEffects of tolcapone in Parkinson's patients taking L-dihydroxyphenalalanine/carbidopa and selegiline
003567 C. G. Goetz [États-Unis] ; G. T. Stebbins ; J. A. ThelenTalipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial
003594 Olivier Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. RascolNaltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
003648 C. W. Olanow [États-Unis] ; S. Fahn ; M. Muenter ; H. Klawans ; H. Hurtig ; M. Stern ; I. Shoulson ; R. Kurlan ; J. D. Grimes ; Joseph Jankovic [États-Unis] ; M. Hoehn ; C. H. Markham ; R. Duvoisin ; O. Reinmuth ; H. A. Leonard ; E. Ahlskog ; R. Feldman ; L. Hershey ; M. D. YahrA multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet® in Parkinson's disease
003672 C. Pacchetti [Italie] ; E. Martignoni [Italie] ; P. Bruggi [Italie] ; L. Godi [Italie] ; B. Aufdembrinke ; C. Miltenburger ; B. Voet ; G. Nappi [Italie]Terguride in fluctuating Parkinsonian patients: a double-blind study versus placebo

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024